Statement on FDA Decision to Approve OTC Primatene Mist
The following is a statement by Allergy & Asthma Network:
Allergy & Asthma Network is disappointed by FDA’s decision to approve Primatene Mist for over-the-counter use in people with mild and intermittent asthma.
Primatene Mist does not treat asthma — it treats only symptoms that come from asthma. Furthermore, the active ingredient in Primatene Mist — racemic epinephrine — is not recommended for use in asthma.
If you are experiencing asthma symptoms, it is important to consult with your doctor to determine how best to manage your disease. Overuse of a quick-relief medication such as Primatene Mist is a primary indicator of uncontrolled asthma and is an unrecognized red flag in most reported deaths.
Asthma is a life-threatening chronic disease that is not easily diagnosed or managed. Ten Americans die each day due to asthma and those deaths are distributed equally among mild, moderate and severe asthma.
Allergy & Asthma Network supports patients, caregivers and healthcare professionals. We are committed to ending needless death and suffering to asthma, allergies and related conditions. Please contact us at firstname.lastname@example.org or 1-800-878-4403 for more information.